Literature DB >> 8043227

HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.

A R Moss1, K Vranizan, R Gorter, P Bacchetti, J Watters, D Osmond.   

Abstract

OBJECTIVE: To examine the HIV seroconversion rate, risk factors for seroconversion, and changes in risk behavior over time in intravenous drug users (IVDU) in San Francisco, 1985-1990.
DESIGN: Observational study.
SETTING: All methadone maintenance and 21-day methadone detoxification programs in San Francisco. PARTICIPANTS: A total of 2351 heterosexual IVDU, of whom 681 were seronegative at first visit and seen at least twice ('repeaters'). MAIN OUTCOME MEASURES: HIV seroconversion rates, risk factors for seroconversion, and changes in behavior.
RESULTS: The HIV seroconversion rate in repeaters was 1.9% per person-year (ppy) of follow-up [2.1% in women versus 1.7% in men (not significant); 4% in African Americans versus 1% in whites (P = 0.006); 3.9% ppy in the first third of the study, 1.2% in the second (P = 0.007), and 1.9% in the last (not significant)]. Risk factors for seroconversion were five or more sexual partners per year [hazard ratio (HR) = 2.6; P = 0.02], use of shooting gallery ever (HR = 2.9; P = 0.02), and less than 1 year (lifetime) in methadone maintenance (HR = 2.7; P = 0.02). Self-reported intravenous cocaine use fell from 33 to 15% over 5 years, shooting gallery use fell from 19 to 6%, and the proportion with five or more sexual partners fell from 25 to 10%. Bleach use rose to 75% of needle-sharers.
CONCLUSIONS: The 1985-1990 HIV seroconversion rate in IVDU (1.9% ppy) was comparable to that in San Francisco cohorts of homosexual men (1.4% ppy). A decline in HIV seroconversion coincided with changes in risk behavior. Stable attendance of methadone maintenance was highly protective: the seroconversion rate in subjects with 1 year or more in methadone was 12% ppy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043227     DOI: 10.1097/00002030-199402000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  40 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: implications for public health intervention.

Authors:  K Clements-Nolle; R Marx; R Guzman; M Katz
Journal:  Am J Public Health       Date:  2001-06       Impact factor: 9.308

3.  Sex-specific determinants of HIV infection among injection drug users in Montreal.

Authors:  J Bruneau; F Lamothe; J Soto; N Lachance; J Vincelette; A Vassal; E L Franco
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

4.  Assessing the effects of human mixing patterns on human immunodeficiency virus-1 interhost phylogenetics through social network simulation.

Authors:  Steven M Goodreau
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

Review 5.  HIV prevention among injection drug users: the need for integrated models.

Authors:  David S Metzger; Helen Navaline
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

6.  Social contextual factors associated with entry into opiate agonist treatment among injection drug users.

Authors:  Jacqueline J Lloyd; Erin P Ricketts; Steffanie A Strathdee; Llewellyn J Cornelius; David Bishai; Steven Huettner; Jennifer R Havens; Carl Latkin
Journal:  Am J Drug Alcohol Abuse       Date:  2005       Impact factor: 3.829

7.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 8.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

9.  Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City.

Authors:  D M Hartel; E E Schoenbaum
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 10.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.